Fig. 4: Comparisons of antibody titers of short (4–6 weeks, n = 25) and long (8–10 weeks, n = 25) vaccine dosing intervals. | Nature Communications

Fig. 4: Comparisons of antibody titers of short (4–6 weeks, n = 25) and long (8–10 weeks, n = 25) vaccine dosing intervals.

From: A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19

Fig. 4

Neutralizing antibody titers were measured by ELISA-based method. The values in international units per milliliter (IU/mL) are provided. Data are presented as geometric mean ±95% confidence intervals. The significance between two dose intervals was determined using t test (two-tailed). Comparisons of antibody titers for the heterologous MVC-COV1901 group, Day 0, P = 0.2720; Day 10 ± 3, P = 0.0250; Day 28 ± 3, P = 0.0050. Comparisons of antibody titers for the homologous ChAdOx1 group, Day 0, P = 0.0270; Day 10 ± 3, P = 0.0480; Day 28 ± 3, P = 0.2630. *P  <  0.05, **P  <  0.01, NS not significant. Source data are provided as a Source Data file.

Back to article page